ARMP — Armata Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $51.38m
- $136.48m
- $5.17m
Annual income statement for Armata Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.823 | 4.47 | 5.51 | 4.53 | 5.17 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 23.5 | 27.6 | 42.5 | 49.3 | 45.4 |
| Operating Profit | -22.7 | -23.1 | -36.9 | -44.8 | -40.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -22.2 | -23.2 | -36.9 | -69 | -18.9 |
| Net Income After Taxes | -22.2 | -23.2 | -36.9 | -69 | -18.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -22.2 | -23.2 | -36.9 | -69 | -18.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -22.2 | -23.2 | -36.9 | -69 | -18.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.22 | -0.991 | -1.08 | -1.81 | -0.583 |